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Abstract
Purpose Pathologic complete response is associated with longer disease-free survival and better overall survival after neo-
adjuvant chemotherapy in breast cancer patients. We, therefore, evaluated factors influencing pathologic complete response.
Methods Patients receiving neoadjuvant chemotherapy from 2015 to 2018 at the Saarland University Hospital were included. 
Patients’ age, tumor stage, tumor biology, genetic mutation, recurrent cancer, discontinuation of chemotherapy, and participa-
tion in clinical trials were extracted from electronic medical records. Binary logistic regression was performed to evaluate 
the influence of these factors on pathologic complete response.
Results Data of 183 patients were included. The median patient’s age was 54 years (22–78). The median interval between 
diagnosis and onset of chemotherapy was 28 days (14–91); between end of chemotherapy and surgery 28 days (9–57). Sixty-
two patients (34%) participated in clinical trials for chemotherapy. A total of 86 patients (47%) achieved pathologic complete 
response. Patient’s age, genetic mutation, recurrent cancers, or discontinuation of chemotherapy (due to side effects) and 
time intervals (between diagnosis and onset of chemotherapy, as well as between end of chemotherapy and surgery) did not 
influence pathologic complete response. Patients with high Ki67, high grading, Her2 positive tumors, as well as patients 
participating in clinical trials for chemotherapy had a higher chance of having pathologic complete response. Patients with 
Luminal B tumors had a lower chance for pathologic complete response.
Conclusion Particularly patients with high risk cancer and patients, participating in clinical trials benefit most from chemo-
therapy. Therefore, breast cancer patients can be encouraged to participate in clinical trials for chemotherapy.
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Introduction
Neoadjuvant chemotherapy (NACT) has changed its role for 
only inoperable and locally advanced breast cancer to a treat-
ment used in early stages of breast cancer [1]. Particularly 
patients at high risk, like patients with Her2 positive and 
triple-negative breast cancer benefit from receiving NACT 
[2, 3]. Pathological complete response (pCR) is associated 
with a better outcome, meaning that patients having pCR 
have longer disease-free survival and better overall survival 
[5].
The definition of pCR varies in individual studies (ypT0/
ypTis/ypN0). However, it could be shown that no residual 
invasive cancer in the breast and axilla is associated with 
better outcomes compared with no residual cancer in the 
breast alone [4]. Von Minckwitz et al. even detected a longer 
disease-free survival in patients with no invasive and no 
in situ carcinoma in the breast and axilla [5]. Also, tumor 
subtypes influence the achievement of pCR and thus a bet-
ter outcome. For example, LeVasseur et al. detected that 
patients with triple negative tumors had longer relapse-free-
survival and breast cancer-specific survival when achieving 
pCR after NACT [6].
As pCR plays an important role in the outcome of breast 
cancer, several studies already evaluated possible influencing 
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factors, like age of the patients [7, 8], tumor biology [9] or 
genetic mutation [10]. The majority of the cited studies ana-
lyzed data that was previously collected as part of NACT 
trials. But patients who are included in clinical studies are 
mostly a selected collective due to in- and exclusion crite-
ria with fewer previous illnesses, or of a certain subtype or 
tumor size. For this reason, we wanted to analyze possible 
influencing factors on pCR in “real-world-data”.
Although, some factors such as age, tumor biology or 
genetic mutation cannot be influenced directly, it is still 
important to identify possible risk factors to maybe estab-
lish further follow-up therapies or intensified aftercare. We, 
therefore, determined various clinical factors from electronic 
patient records and evaluated their influence on the prob-
ability of pCR. Parts of the registry were used for two other 
analyzes before [11, 12]. We could show that especially 
inpatient and outpatient presentations of the patients delayed 
therapy onset of NACT and surgery [11, 12].
Patients and methods
Data collection
All patients receiving NACT due to newly diagnosed breast 
cancer between 2015 to 2018 at the Department of Gyne-
cology, Saarland University Medical Center, were included 
in the study. The primary endpoint was pCR after NACT. 
pCR was defined as no residual tumor in the breast and 
axilla (ypT0, N0). It includes no residual Tis (Carcinoma 
in situ). Date of diagnosis was defined as the date of core 
biopsy. Patients’ age, tumor stage, eventual multi-centric-
ity, and tumor biology were recorded. It was distinguished 
whether the patients received NACT as standard therapy or 
in a clinical trial. Mainly GAIN II [13], Gepar Octo [14], 
and Gepar X [15] were addressed from 2015 to 2018 in the 
Saarland University Medical Center as clinical trials. The 
time interval between diagnosis and onset of chemotherapy, 
as well as between end of chemotherapy and surgery, was 
recorded. The type of operation and duration of hospitaliza-
tion were documented. Patients who had an indication for 
BRCA testing according to the guidelines of the German 
AGO Mamma and the German Consortium for Hereditary 
Breast and Ovarian Cancer (GC-HBOC) were tested for a 
BRCA mutation. Their recommendations are based on an 
analysis of 21,401 families [16]. It was registered whether 
patients had a genetic mutation (BRCA) or recurrent cancer. 
Recurrent cancer was defined as local recurrence of breast 
cancer. Patients with local recurrence were included in the 
study regardless of their previous therapy. If patients dis-
continued chemotherapy due to therapy complications or 
disease progress, it was recorded as well.
Data management and statistics
Patients’ data were reviewed in the hospital’s digital 
documentation system (SAP, Walldorf, Germany). Data 
were collected using Microsoft Excel  2010® (Microsoft, 
Redmond, USA). Further statistics were performed with 
SPSS 24.0 (IBM, Armonk, USA). Quantitative parameters 
(e.g., patients age, days) are given as median and range. 
Qualitative parameters (e.g., tumor stage) are presented 
as frequencies. Binary logistic regression was performed 
to determine the influence of multiple factors on pCR. 
Possible influencing factors were age, study participation, 
tumor biology, genetic mutation (BRCA), recurrent can-
cer, discontinuation of chemotherapy (due to side effects), 
days between diagnosis and begin of chemotherapy as well 
as days between end of chemotherapy and operation. All 
procedures performed in the study involving human par-
ticipants were in accordance with the ethical standards 
of the institutional and national research committee and 
with the 1964 Helsinki Declaration and its later amend-
ments or comparable ethical standards. Informed consent 
was obtained from every individual participant included 
in the study.
Results
Between 2015 and 2018, a total of 205 patients received 
NACT due to newly diagnosed breast cancer at the Saar-
land University Medical Center. Twenty-two patients had 
to be excluded because of insufficient data so that the data 
of 183 patients were analyzed. The patients median age 
was 54 years (22–78). The median time between diagnosis 
and begin of NACT was 28 days (14–91). Between the end 
of NACT and operation, median time was 28 days (9–57).
Tumor stage and biology, as well as histological sub-
type and grading are illustrated in Table 1. Twenty-eight 
patients (15%) had multicentricity. BRCA mutation (9 
patients, 5%) and recurrent cancers (7 patients, 4%) were 
rare. Sixty-two patients (34%) received study therapies: 
GAIN II (12%), Gepar Octo (10%), GeparX (9%), others 
(5%). Patients participating in clinical studies had a higher 
percentage of triple negative tumors (42%) compared to 
patients without study treatment (26%). Her2 positive 
tumors are less frequent in the study group (34%), com-
pared to standard therapy regimen (39%). Furthermore, 
Grading and Ki67 values are higher in patients partici-
pating in clinical trials (Grading G3 67% vs. 53%, Ki67 
50% vs. 40%). All patients received an Anthracycline 
and Taxane-based chemotherapy. Fifty-four patients of 
the Her2 positive group (79%) received chemotherapy 
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in combination with Trastuzumab and Pertuzumab, 21% 
received chemotherapy in combination with Trastuzumab 
alone. All patients with triple-negative carcinoma addi-
tionally received carboplatin. Thirty-four patients (19%) 
discontinued NACT. Twenty patients (11%) skipped only 
the last or the last two chemotherapy doses, whereas 14 
patients (8%) received three or more than three doses 
less. The reasons for a premature discontinuation of 
Table 1  Tumor characteristics
HR  hormone receptor

















 pN0 (sentinal node) 83 45.4
 pN+ 100 54.6




NST (invasive carcinoma of no special type) 173 94.5
Others 10 5.5





HR+, Her2 neg, Ki67 ≤ 15% 8 4.4
Luminal B
HR+, Her2 neg, Ki67 > 15% 50 27.3
Her2 positive, HR positive 48 26.2
Her2 positive, HR negative 20 11.0
Triple negative 57 31.1
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chemotherapy were equally distributed in both groups; the 
major part (16%) due to side effects (polyneuropathy 7%, 
changes in laboratory values as increased liver values or 
cytopenia 6%, others 3%). Four patients (2%) discontinued 
NACT because of tumor progression.
Most patients received breast-conserving therapy 
(63%), followed by mastectomy (22%) and oncoplastic sur-
gery (15%). Implants or expander was used for 24 patients 
(13%). The median time of hospitalization during the oper-
ation was 4 days (1–22). Patients with breast-conserving 
therapy had a median time of hospitalization of 3 days 
(1–14), patients undergoing mastectomy 6 days (2–17) and 
patients with oncoplastic surgery 7 days (2–22).
A total of 86 patients (47%) had pCR. The patients age, 
genetic mutation, recurrent cancer, or discontinuation of 
chemotherapy (due to side effects) did not influence pCR. 
Likewise, time between diagnosis and onset of NACT, or 
time between end of NACT and surgery, had no influence 
on pCR. Patients participating in clinical trials for NACT, 
higher tumor grade, high Ki67 and Her2 positive tumors 
had increased chances of having pCR. Patients with Lumi-
nal B tumors had a lower chance of achieving pCR. No 
pCR was detected in the Luminal A group. In patients with 
triple negative tumors, a trend could be observed. They 
seem to have more often pCR, although not statistically 
significant. Influences on pCR are shown in Table 2.
Discussion
This study presents several influences on pCR, with 
increased chances in patients participating in studies for 
NACT, having a high Ki67, high grading or Her2 posi-
tive tumors. Tumor subtypes like Luminal A and B had 
decreased chances of pCR.
Age had no influence on pCR in the current study. In 
contrast, other studies reported that young age is posi-
tively associated with pCR [7]. A cutoff value of 40 years 
was proposed under which the chances of pCR may be 
higher [17]. However, pCR can also be achieved in elderly 
patients, especially for Her2 positive patients [8]. So, age 
alone should not be an indication for NACT.
Neither time between diagnosis and onset of NACT, nor 
time between the end of chemotherapy and surgery influ-
enced pCR. Consistently, exceeding a presumed cut-off of 
4 weeks for onset of NACT or surgery did not influence 
pCR and disease-free or overall survival independent of 
histopathological subgroups [18]. However, it was sus-
pected that patients without pCR could benefit from early 
surgery [18]. At least time intervals up to 8 weeks between 
NACT and surgery seem not to influence outcomes [19]. 
In the present study, the median time from diagnosis to 
NACT and NACT to surgery was about a month with only 
a minor part exceeding 8 weeks, which complies with Ger-
man guidelines [20]. This limits the ability to assess the 
influence of longer time intervals on pCR. However, our 
results suggest that therapy intervals seem to have a neg-
ligible influence on pCR.
More than a third of our patients participated in clinical 
trials. Study participants for NACT had more than twice 
as high a chance to achieve pCR. In addition to higher 
chances for pCR in patients participating in clinical trials, 
mastectomy rates were lower [21]. However, one must take 
into account that the patients who are included in clinical 
studies are mostly a selected collective. On the one hand, 
this means that there is a disproportionate part of those 
patients who have a higher probability to achieve pCR 
due to tumor biology (e.g. high grading and high Ki67). 
On the other hand, study patients have fewer previous ill-
nesses due to in- and exclusion criteria which can other-
wise lead to premature discontinuation of therapy, dose 
reduction or longer therapy breaks. In the present study, 
patients receiving NACT in clinical trials had higher rates 
of Ki67 and higher grading compared to patients receiving 
standard therapy. This might be the reason for higher pCR 
rates in the study participants. Furthermore, there was a 
higher percentage with triple negative tumors in the study 
group comparing to standard treatment. However, the rate 
of Her2 positive tumors (which are also associated with 
higher rates of pCR) was lower in patients participating 
Table 2  Influences on pCR by binary logistic regression
Bold values represents statistically significant
Parameter Odds ratio
Exp (B)
P 95% confidence 
interval







Study participation 2.355 0.009 1.244–4.458
Genetic mutation 2.203 0.275 0.533–9.103




Ki67 1.031  < 0.001 1.016–1.047
Grading 4.201  < 0.001 2.206–7.999







Luminal B 0.297 0.001 0.144–0.616
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in clinical trials. Nevertheless, we should encourage our 
patients to participate in clinical trials. Besides contribut-
ing to therapy improvements, they most likely benefit from 
new therapies. Possible disadvantages of trial participa-
tion, such as delaying the onset of NACT or surgery, could 
be excluded [11, 12].
Only 5% of our patients had a proven genetic mutation 
(BRCA) for which a superior response to NACT was pre-
viously described [10]. Particularly when BRCA positive 
patients have triple-negative tumors, better outcomes are 
suspected [22]. We could not prove a significant influence 
of genetic mutation on pCR.
Likewise, there was no influence of local recurrent can-
cers on pCR. To our knowledge, this is the first study ana-
lyzing a possible influence of local recurrent cancers on 
the pCR rate. However, no distinction was made whether 
patients already received prior chemotherapy. In contrast to 
that, there are analyses describing the association of pCR 
after NACT on the recurrence of locoregional cancer. An 
analysis of 10,075 women showed that the local recurrence 
rate after chemotherapy was higher in patients with non-pCR 
(9.5% in 67 months) [23].
Discontinuation of chemotherapy due to intolerable side 
effects did not influence pCR. Patients discontinuing NACT 
due to disease progress were not included. In general, guide-
lines recommend the completion of chemotherapy [20]. Our 
results imply that discontinuation of chemotherapy may not 
substantially lower chances for pCR. However, it should 
be considered that this might be due to the small sample 
size and that most patients only discontinued before the last 
or the last two chemotherapy doses. Nevertheless, a detri-
mental effect of early termination of chemotherapy cannot 
be excluded. Peripheral neurotoxicity was the most com-
mon reason why patients had to discontinue chemotherapy 
(7%). Unfortunately, therapeutic options like pharmacologi-
cal treatments are limited [24]. Thus, only dose reduction 
or discontinuation are current options [24]. Nevertheless, 
premature discontinuation of NACT seems to be uncriti-
cal, especially when a good clinical response was already 
proven. Further studies are needed to confirm our findings.
Ki67 and high grading were associated with high pCR 
rates (P < 0.001). As Ki67 increases by 1, the probability 
of a pCR increases by 1.031. This is consistent with find-
ings that especially highly aggressive tumors have a good 
response to chemotherapy [5, 25]. Triple-negative tumors 
tend to have better pCR rates without reaching statistical 
significance. Other studies already showed that triple-neg-
ative tumors (as aggressive tumors) were associated with 
higher pCR rates after NACT [5, 7]. Her2 positive tumors 
showed higher chances for pCR in our study. This has also 
been demonstrated in previous studies [26, 27]. It could be 
shown that patients with Her2 positive, hormone receptor 
(HR) negative tumors showed the highest rates of pCR. With 
this tumor biology (Her2+, HR−) the chance to achieve pCR 
was 4.5 times higher than in other tumor subtypes. Von 
Minckwitz et al. and Harbeck et al. also observed that Her2 
positive tumors respond particularly well to NACT when 
hormone receptor status is negative [5, 28]. In the present 
study, even tumors with Her2 positive, hormone receptor 
positive tumors had a twice as high chance to achieve pCR 
(P = 0.045). This effect could not be shown in all previous 
studies [5]. One reason for this might be the change in Her2 
directed therapy, as the addition of pertuzumab to trasu-
zumab and NACT led to a more frequent pCR rate [29, 30]. 
In the present study, most patients (79%) received Trastu-
zumab and Pertuzumab. Only a minor part (21%) received 
Trastuzumab alone.
The subtype Luminal B was associated with a lower 
chance for pCR. Available data seem contradictory. pCR 
seems to appear more likely in young patients with hormone 
receptor-positive, Her2 negative breast cancer [7]. However, 
large analyzes of 13,939 women showed that the lowest rate 
of pCR was achieved for Luminal A, followed by Lumi-
nal B subtypes, whereas pCR rates of triple-negative and 
Her2 positive were comparatively higher [27]. Also, patients 
with progesterone negativity showed higher pCR rates [9]. 
Taken together, high Ki67, high grading and Her2 positive 
tumors are notably associated with higher pCR. No pCR 
was detected in the Luminal A group. This seems not to be 
surprisingly, as Luminal A cancers are not appropriate for 
NACT and normally show the lowest rates of pCR [27]. In 
this analysis, the four patients with Luminal A cancers had 
locally advanced tumors and received chemotherapy there-
fore neoadjuvant.
This study has limitations. It is single centric, and thus 
clinical pathways may differ to other centers. However, data 
were collected from a certified tertiary breast care center, 
ensuring that therapies are state of the art. The sample size is 
small, but many other studies are based on registers obtained 
from clinical trials for new therapy regimes [5, 7–9, 18, 21], 
which implies selection bias due to specific inclusion crite-
ria. Our data more likely represents “real-world-data”.
Conclusion
Particularly patients with aggressive tumors (high Ki67, 
high grading, Her2 positive tumors) had better response 
rates on NACT. These patients should receive chemotherapy 
in a neoadjuvant setting. Furthermore, patients participating 
in clinical trials had higher pCR rates after NACT. Besides 
contributing to therapy improvements, they most likely 
benefit from new therapies. We should thus encourage our 
patients to participate in clinical trials.
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